78
Participants
Start Date
January 30, 2018
Primary Completion Date
September 28, 2021
Study Completion Date
July 30, 2026
Carboplatin
Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
Nivolumab
Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
Ohio State University, Columbus
The Stamford Hospital, Stamford
Eastern Maine Medical Center, Bangor
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
St. Elizabeth's Medical Center, Boston
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth
Dana-Farber/New Hampshire Oncology-Hematology, Londonderry
University of Vermont Medical Center, Burlington
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Dana-Farber Cancer Institute
OTHER